# Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia

> **NCT01300364** · PHASE4 · UNKNOWN · sponsor: **Fundació Sant Joan de Déu** · enrollment: 249 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Reboxetine
- **DRUG:** citalopram (SSRI)

## Key facts

- **NCT ID:** NCT01300364
- **Lead sponsor:** Fundació Sant Joan de Déu
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-11
- **Primary completion:** 2011-12
- **Final completion:** —
- **Target enrollment:** 249 (ESTIMATED)
- **Last updated:** 2011-02-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01300364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01300364, "Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01300364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*